NEW YORK (GenomeWeb News) – Cernostics said on Tuesday it is collaborating with the Academic Medical Center in the Netherlands to complete validation studies of the company’s test for cancer in patients with Barrett’s Esophagus.
AMC will provide Cernostics access to its Barrett’s Esophagus patient registry, which Cernostics will use to complete studies of its TissueCypher:Barrett’s. Under the direction of Jacques Bergman, AMC has identified 5,000 patients from 16 hospitals in the Amsterdam region with the ailment, Cernostics said.
The company’s test uses whole slide digital imaging technology to predict which patients with Barrett’s Esophagus may develop esophageal cancer. TissueCypher:Barrett’s will help clarify how the disease should be treated and provide actionable information to clinicians and patients, Cernostics said.
The Pittsburgh-based cancer diagnostics and prognostics firm said last month that it raised $1.4 million in a Series B financing round.